Replies to post #103410 on NanoViricides Inc (NNVC)

[changes_iv]

Your beef, if any, is not with me. Your beef is with news media in general. They are the group publishing articles on the bio-terrorism agent, Ebola.

In other countries, where there is no freedom of the press, the people are blind to what may come but nevertheless those totalitarian regimes take precautions.

Take for example Canada, among 30 other countries. Scared out of their wits even with TKM-Ebola handy?

Why are Australia and Canada following North Korea’s lead on Ebola?

Despite international bodies such as the World Health Organization declaring it a shortsighted and ultimately damaging tactic, the number of countries that are placing restrictions on travel due to Ebola has been rising.

Although precise numbers are a little hard to ascertain (countries are not always forthcoming with their policies), by WorldView's count there appear to be almost 30 countries imposing blanket or near-blanket bans on entry for residents from Ebola's West African epicenter: Liberia, Sierra Leone and Guinea. Many of these countries are also banning entry for their own citizens who have visited the epicenter recently.

http://www.washingtonpost.com/blogs/worldviews/wp/2014/11/06/why-are-australia-and-canada-following-north-koreas-lead-on-ebola/

Is there a post-HIV syndrome or post-Herpes(shingles) syndrome?

Post-zEbola syndrome...
West Africans fortunate to survive Ebola may go on to develop what's being called "post-Ebola syndrome," characterized by vision loss and long-term poor health, a doctor told a World health Organization.

https://gma.yahoo.com/post-ebola-syndrome-persists-virus-cured-doctor-says-181100681--abc-news-topstories.html

The war against Ebola should be fought over there, in West Africa, in the hotbeds of Ebola and currently there are Ebola vaccine trials in Mali. Hopefully they will help prevent the spread. It is over there where people must be quarantined and treated. It is wise to err on the side of caution, in the least risky manner in a situation (Ebola spread) in which one is uncertain about the consequences.

Currently there is only one small biotech company that may ERRADICATE Ebola from a host and that is NanoViricides, Inc.. We also have a state-of-the-art CGMP Pilot Plant in Connecticut.

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”), a nanomedicine company developing anti-viral drugs, announced today that it has executed a CRADA (Collaborative Research and Development Agreement for Material Transfer) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Certain novel anti-Ebola nanomedicine drug candidates recently developed by the Company will be evaluated by USAMRIID scientists in their BSL-4 facilities for activity against the deadly Ebola virus under this agreement.

"We are very happy to restart our collaboration with USAMRIID for developing an effective drug against the deadly Ebola virus," said Dr. Eugene Seymour, MD, MPH, CEO of NanoViricides, Inc., adding, "We intend to ship the samples as soon as the synthesis of the new drug candidates is completed."

The current Ebola epidemic that began in West Africa around December 2013-February 2014, has started producing sporadic cases elsewhere in the world. All of these cases have originated with people that have been to the epidemic-affected regions. However, local transmission has occurred in health care workers in the USA as well as in Spain. This epidemic continues to expand both geographically and numerically, exponentially, and containment efforts have had a very limited impact to date. More than 4,500 deaths have been reported, with a case fatality rate estimated at about 70%. As important as control measures are to limit the disease spread, a therapeutic drug is absolutely needed to effectively contain such a rapidly spreading epidemic.

There are currently no effective drugs or vaccines available for combating Ebola virus infection. The few cases of successful treatment with potential drug candidates had also received serum from survivors.

NanoViricides undertook the extreme challenge of developing a drug to combat this disease in a "war-like" timeline. We believe that we can develop an effective drug rapidly compared to other approaches, because of the inherent strength of our nanoviricides® platform technology.

The Company has recently developed and is now synthesizing test quantities of its novel nanoviricide drug candidates against Ebola that it believes could lead to a successful therapeutic. These drug candidates are designed to mimic the host cell receptor onto which the Ebola virus binds to cause an infection. The site at which the virus binds does not change, in spite of mutations. Thus the Company believes that its drug candidates would continue to work in spite of field mutations in the virus. This is unlike vaccines, antibodies, siRNA, antisense, and several other therapeutic modes, which a virus can readily overcome due to mutations it acquires in the field.

http://www.nanoviricides.com/press%20releases/2014/NanoViricides,%20Inc.%20Signs%20CRADA%20for%20Material%20Transfer%20with%20USAMRIID%20for%20Evaluating%20Its%20Anti-Ebola%20Drug%20Candidates.html

EbolaCide2 - Plan of attack
Re: USAMRIID

Corinne (Scully) is gone and Gene (Olinger) is at the NIH virology labs

I'm in touch with Gene and would love to work with him.

We're shooting for a mid-November ship date but that's completely dependent on completing the synthesis of all the variants. Usually we make 8 variants, send them for testing, take the best two, expand them and make another eight.

This time, we're making many more and they'll all be tested during the same pass to save time. If this works as we hope, I want to get EbolaCide to Africa ASAP!

EUGENE SEYMOUR - Chief Executive Officer & Director
October 31, 2014

www.siliconinvestor.com/subject.aspx?subjectid=55797

I wrote to my senators at the U.S. Congress to exhort them and join senator Richard Blumenthal of CT in his support to speed up efficacy testing of EbolaCide2 at USAMRIID bsl-4 facilities. I also requested streamlining of FDA Regulations (obstacles) of low toxicity and potentially life-saving FluCide? Did you? I did not ask for money for my small biotech company. Don't just gripe about elections and perceptions, do something about it!

We will soon enough find out who is right about efficacy and EbolaCide. And I figure the news media will be asking about what else we have in the drug pipeline.